| Glioma Diagnosis and Treatment | Lifetime | 51 | AT 1 | 99.77 |
| Brain Metastases and Treatment | Lifetime | 25 | AT 1 | 99.72 |
| Meningioma and schwannoma management | Lifetime | 63 | AT 1 | 99.51 |
| Lung Cancer Research Studies | Lifetime | 137 | AT 1 | 99.37 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 271 | AT 1 | 99.34 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 349 | AT 5 | 98.83 |
| Lung Cancer Treatments and Mutations | Lifetime | 542 | AT 3 | 98.80 |
| Cancer Genomics and Diagnostics | Lifetime | 681 | AT 2 | 98.77 |
| Neuroblastoma Research and Treatments | Lifetime | 417 | AT 6 | 97.77 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 220 | AT 1 | 97.52 |
| Melanoma and MAPK Pathways | Lifetime | 326 | AT 4 | 96.58 |
| COVID-19 and healthcare impacts | Lifetime | 825 | AT 1 | 92.61 |
| Pituitary Gland Disorders and Treatments | Lifetime | 950 | AT 5 | 95.87 |
| Chromatin Remodeling and Cancer | Lifetime | 226 | AT 2 | 94.33 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 579 | AT 7 | 93.70 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 851 | AT 26 | 89.24 |
| Glioma Diagnosis and Treatment | 2021-2025 | 5 | AT 1 | 99.87 |
| Meningioma and schwannoma management | 2021-2025 | 4 | AT 1 | 99.55 |
| Brain Metastases and Treatment | 2021-2025 | 5 | AT 1 | 99.74 |
| Neuroblastoma Research and Treatments | 2021-2025 | 41 | AT 1 | 97.96 |
| Lung Cancer Research Studies | 2021-2025 | 153 | AT 2 | 97.96 |
| Cancer Treatment and Pharmacology | 2021-2025 | 171 | AT 2 | 96.72 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 70 | AT 1 | 94.48 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 344 | AT 3 | 93.20 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 322 | AT 4 | 93.10 |
| Medical Imaging Techniques and Applications | 2021-2025 | 983 | AT 16 | 90.84 |
| Management of metastatic bone disease | 2021-2025 | 297 | AT 5 | 85.81 |
| HER2/EGFR in Cancer Research | 2021-2025 | 972 | AT 8 | 84.86 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 752 | AT 9 | 75.70 |
| Chromatin Remodeling and Cancer | 2021-2025 | 674 | AT 3 | 61.49 |
| GDF15 and Related Biomarkers | 2021-2025 | 799 | AT 12 | 47.08 |
| Apelin-related biomedical research | 2021-2025 | 766 | AT 9 | 31.74 |
| Chemotherapy-related skin toxicity | 2021-2025 | 944 | AT 15 | 23.38 |
